financetom
Business
financetom
/
Business
/
Nissan explores hybrid rollout in South Africa to smooth the shift to EVs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nissan explores hybrid rollout in South Africa to smooth the shift to EVs
Sep 9, 2025 8:48 AM

By Nqobile Dludla

JOHANNESBURG (Reuters) -Japan's Nissan Motor Co ( NSANF ) is considering a rollout of hybrid cars that use its e-Power technology in South Africa as a way to help drivers move from petrol engines towards electric vehicles, a company executive said on Tuesday.

Low incomes and high import duties have long hampered manufacturers' efforts to sell more cars in Africa, with patchy power access and a lack of sufficient charging infrastructure posing additional hurdles for EV adoption on the continent.

Nissan ( NSANF ) has already launched hybrids in Morocco, Egypt and Tunisia that run on the e-Power system, which the company thinks could also be popular among South African drivers.

"This is currently under study," Ramy Mohareb, communications head for Nissan Africa, told reporters, adding that the company was evaluating factors such as customer demand and market readiness.

"Why we're saying it fits Africa, is because you don't need the extensive infrastructure, and battery cost is not as high as the current EVs. There is no range anxiety. So we think that this is the right technology to transition to full EVs in Africa."

Nissan's ( NSANF ) e-Power system is an electrified powertrain that combines a compact gasoline engine and an electric motor. It uses electricity generated by the engine to drive the vehicle solely with the electric battery.

Mohareb was speaking at the launch of Nissan's ( NSANF ) newer models of its X-Trail SUV and Magnite Kuro compact SUV.

Maciej Klenkiewicz, managing director for Nissan Africa, emphasised the company's commitment to South Africa amid a major global restructuring.

"Africa is in quite good shape ... We are not shrinking, we're going to increase that portfolio," he said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Largo Narrows Q4 Net Loss, Details Operational Turnaround Plan, Optimization Initiatives
Largo Narrows Q4 Net Loss, Details Operational Turnaround Plan, Optimization Initiatives
Mar 31, 2025
07:19 AM EDT, 03/31/2025 (MT Newswires) -- Largo (LGO.TO) late on Friday reported that its fourth-quarter net loss narrowed as revenues fell. Net loss was US$13 million, or or a loss of US$0.19 per share, narrowing from a loss of US$13.3 million, or a loss of US$13.3 million. Revenues came in at US$24.3 million, down from US$44.2 million. Adjusted EBITDA...
Yum Brands CEO Gibbs to retire in 2026
Yum Brands CEO Gibbs to retire in 2026
Mar 31, 2025
March 31 (Reuters) - KFC ( YUM ) parent Yum Brands ( YUM ) said on Monday CEO David Gibbs has informed the board of his intention to retire from the company next year. Gibbs, who joined the company in 1989 as an executive for Taco Bell, took on the role of Yum's chief executive officer in January 2020. The...
Germany's DHL to acquire U.S. pharma logistics firm Cryopdp, source says
Germany's DHL to acquire U.S. pharma logistics firm Cryopdp, source says
Mar 31, 2025
DUSSELDORF, Germany, March 31 (Reuters) - Germany's DHL has agreed to acquire U.S. pharmaceutical logistics firm Cryopdp for a three-digit million-euro sum, a source familiar with the matter said on Monday. (Reporting by Matthias Inverardi, Writing by Rachel More, Editing by Thomas Seythal) ...
Astrazeneca Receives Approval Recommendation for Calquence Combination Therapy in Europe
Astrazeneca Receives Approval Recommendation for Calquence Combination Therapy in Europe
Mar 31, 2025
07:17 AM EDT, 03/31/2025 (MT Newswires) -- Astrazeneca ( AZN ) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval for Calquence, in combination with bendamustine and rituximab, as a treatment for adult patients with previously untreated mantle cell lymphoma. The company said the recommendation was based on the results of a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved